Comment on Nuño Solinís R, et al. “Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence”

Abstract : As demonstrated in the review by Nuño Solinís et al. [4], we now have highly effective, well-tolerated, and cost-effective therapies to treat essentially anyone who is infected with HCV. With these tools, we can prevent not only hepatic but also many extrahepatic diseases caused by HCV. As such, I believe that interferon-free DAA therapy should be offered to most patients that have HCV EHMs as well as to all patients at risk of developing them. This stands out as the best approach to deal with the serious complications of chronic HCV infection and to speed the way to a world in which HCV is effectively eradicated.
Liste complète des métadonnées

Littérature citée [9 références]  Voir  Masquer  Télécharger

https://hal.sorbonne-universite.fr/hal-01587364
Contributeur : Gestionnaire Hal-Upmc <>
Soumis le : jeudi 14 septembre 2017 - 10:30:19
Dernière modification le : mercredi 21 mars 2018 - 18:57:55

Fichier

s40121-017-0155-0.pdf
Publication financée par une institution

Licence


Distributed under a Creative Commons Paternité - Pas d'utilisation commerciale 4.0 International License

Identifiants

Collections

UPMC | I3

Citation

Patrice Cacoub. Comment on Nuño Solinís R, et al. “Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence”. Infectious Diseases and Therapy, 2017, 6 (2), pp.297-301. 〈10.1007/s40121-017-0155-0〉. 〈hal-01587364〉

Partager

Métriques

Consultations de la notice

144

Téléchargements de fichiers

29